Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):
|
Large Accelerated filer ¨
|
Accelerated Filer ¨
|
Non-Accelerated Filer ¨
|
Smaller Reporting Company x
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes o No x
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of August 10, 2011 the issuer had outstanding 247,112,408 shares of common stock, $0.001 par value (exclusive of 100,000 shares held in treasury).
Explanatory Note
The purpose of this Amendment No. 1 to Elite Pharmaceuticals’ Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011, filed with the Securities and Exchange Commission on August 15, 2011 (the “Form 10-Q”), is solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language).
No other changes have been made to the Form 10-Q. This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.
Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.
|
Item 6.
|
Exhibits.
|
| |
|
|
31.1
|
Certification of Chief Executive Officer pursuant to Section 302 of the SOX of 2002*
|
| |
|
|
31.2
|
Certification of Chief Financial Officer pursuant to Section 302 of the SOX of 2002*
|
| |
|
|
32.1
|
Certificate of Chief Executive Officer pursuant to 18 U.S.C.ss.1350*
|
| |
|
|
32.2
|
Certificate of Chief Financial Officer pursuant to 18 U.S.C.ss.1350*
|
| |
|
|
101.INS
|
XBRL Instance Document
|
| |
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
| |
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
| |
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
| |
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
| |
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
* These exhibits were previously included or incorporated by reference in Elite’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2011, filed with the Securities and Exchange Commission on August 15, 2011.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
|
|
ELITE PHARMACEUTICALS, INC.
|
| |
|
|
|
|
Date:
|
August 19, 2011
|
|
/s/ Jerry Treppel
|
| |
|
|
Jerry Treppel
|
| |
|
|
Chief Executive Officer
|
| |
|
|
(Principal Executive Officer)
|
| |
|
|
|
|
Date:
|
August 19, 2011
|
|
/s/ Carter J. Ward
|
| |
|
|
Carter J. Ward
|
| |
|
|
Chief Financial Officer
|
| |
|
|
(Principal Financial and Accounting Officer)
|